tetano
Editor, Senior Moderator
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):170-172. doi: 10.3760/cma.j.issn.1001-0939.2020.03.004. [h=1][Potential antiviral therapeutics for 2019 Novel Coronavirus].[/h]
[Article in Chinese; Abstract available in Chinese from the publisher]
Li H[SUP]1[/SUP], Wang YM[SUP]1[/SUP], Xu JY[SUP]2[/SUP], Cao B[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] in English, Chinese
The recent outbreak of respiratory illness in Wuhan, China is caused by a novel coronavirus, named 2019-nCoV, which is genetically close to a bat-derived coronavirus. 2019-nCoV is categorized as beta genus coronavirus, same as the two other strains-severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). Antiviral drugs commonly used in clinical practice, including neuraminidase inhibitors (oseltamivir, paramivir, zanamivir, etc.), ganciclovir, acyclovir and ribavirin, are invalid for 2019-nCoV and not recommended. Drugs are possibly effective for 2019-nCoV include: remdesivir, lopinavir/ritonavir, lopinavir/ritonavir combined with interferon-β, convalescent plasma, and monoclonal antibodies. But the efficacy and safety of these drugs for 2019-nCoV pneumonia patients need to be assessed by further clinical trials.
[h=4]KEYWORDS:[/h] 2019 novel coronavirus; Antiviral therapy; Infection
PMID: 32164080 DOI: 10.3760/cma.j.issn.1001-0939.2020.03.004
[Article in Chinese; Abstract available in Chinese from the publisher]
Li H[SUP]1[/SUP], Wang YM[SUP]1[/SUP], Xu JY[SUP]2[/SUP], Cao B[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] in English, Chinese
The recent outbreak of respiratory illness in Wuhan, China is caused by a novel coronavirus, named 2019-nCoV, which is genetically close to a bat-derived coronavirus. 2019-nCoV is categorized as beta genus coronavirus, same as the two other strains-severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). Antiviral drugs commonly used in clinical practice, including neuraminidase inhibitors (oseltamivir, paramivir, zanamivir, etc.), ganciclovir, acyclovir and ribavirin, are invalid for 2019-nCoV and not recommended. Drugs are possibly effective for 2019-nCoV include: remdesivir, lopinavir/ritonavir, lopinavir/ritonavir combined with interferon-β, convalescent plasma, and monoclonal antibodies. But the efficacy and safety of these drugs for 2019-nCoV pneumonia patients need to be assessed by further clinical trials.
[h=4]KEYWORDS:[/h] 2019 novel coronavirus; Antiviral therapy; Infection
PMID: 32164080 DOI: 10.3760/cma.j.issn.1001-0939.2020.03.004